NDLI: Abacavir pharmacogenetics--from initial reports to standard of care.

Please wait, while we are loading the content...

Year: 2017 Volume: 37

Year: 2016 Volume: 36

Year: 2015 Volume: 35

Year: 2014 Volume: 34

Year: 2013 Volume: 33

Year: 2013 Volume: 33 Issue: 12

Year: 2013 Volume: 33 Issue: 11

Year: 2013 Volume: 33 Issue: 10

Year: 2013 Volume: 33 Issue: 9

Year: 2013 Volume: 33 Issue: 8

Year: 2013 Volume: 33 Issue: 7

Guidelines for resident teaching experiences.

Effect of intravenous zanamivir on cardiac repolarization.

Lack of effectiveness of sodium bicarbonate in preventing kidney injury in patients undergoing cardiac surgery: a randomized controlled trial.

Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia.

Role of interleukin-1 inhibitors in the management of gout.

Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study.

Beyond statins: lipid management to reduce cardiovascular risk.

Effectiveness of a pharmacy care management program for veterans with dyslipidemia.

A 7-year case of furosemide-induced immune thrombocytopenia.

Abacavir pharmacogenetics--from initial reports to standard of care.

Ceftaroline-induced eosinophilic pneumonia.

Antidepressant use during early pregnancy and the risk of congenital anomalies.

Year: 2013 Volume: 33 Issue: 6

Year: 2013 Volume: 33 Issue: 5

Year: 2013 Volume: 33 Issue: 4

Year: 2013 Volume: 33 Issue: 3

Year: 2013 Volume: 33 Issue: 2

Year: 2013 Volume: 33 Issue: 1

Year: 2012 Volume: 32

Year: 2011 Volume: 31

Year: 2010 Volume: 30

Year: 2009 Volume: 29

Year: 2008 Volume: 28

Year: 2007 Volume: 27

Year: 2006 Volume: 26

Year: 2004 Volume: 24

Year: 2003 Volume: 23

Year: 2002 Volume: 22

Abacavir pharmacogenetics--from initial reports to standard of care.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Martin, Michael A. Kroetz, Deanna L.
Description	Country affiliation: United States Author Affiliation: Martin MA ( Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.)
Abstract	Abacavir is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus infection as part of a multidrug, highly active antiretroviral therapy regimen. Despite its efficacy, approximately 5% of individuals who receive abacavir develop an immune-mediated hypersensitivity reaction (HSR) that warrants immediate discontinuation of abacavir and switching to an alternative antiretroviral regimen. Abacavir HSR is associated with individuals who carry the 57:01 variant in the human leukocyte antigen B (HLA-B) gene. There is a large volume of evidence to show that those who carry HLA-B57:01 are at significantly increased risk of developing HSR and should not receive abacavir. Pharmacogenetic screening to ensure individuals who carry HLA-B*57:01 do not receive abacavir can reduce the incidence of HSR and is now considered the standard of care before prescribing abacavir. Genetic testing to prevent abacavir HSR is currently one of the best examples of integrating pharmacogenetic testing into clinical practice.
File Format	HTM / HTML
ISSN	02770008
e-ISSN	18759114
DOI	10.1002/phar.1278
Journal	Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Issue Number	7
Volume Number	33
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2013-07-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Pharmacology Anti-hiv Agents Therapeutic Use Dideoxynucleosides Hiv Infections Drug Therapy Administration & Dosage Adverse Effects Antiretroviral Therapy, Highly Active Drug Hypersensitivity Etiology Genetics Virology Hla-b Antigens Pharmacogenetics Reverse Transcriptase Inhibitors Research Support, N.i.h., Extramural
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.

Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.

The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.

Abacavir hypersensitivity reaction: an update.

Abacavir and lamivudine for the treatment of human immunodeficiency virus.

Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.

Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy.

Abacavir pharmacogenetics--from initial reports to standard of care.

Similar Documents

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.

Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.

The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.

Abacavir hypersensitivity reaction: an update.

Abacavir and lamivudine for the treatment of human immunodeficiency virus.

Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.

Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy.

Abacavir pharmacogenetics--from initial reports to standard of care.